What Is Ipamorelin?
Ipamorelin is a pentapeptide growth hormone secretagogue (GHS) — a five-amino-acid compound that mimics ghrelin and stimulates the pituitary gland to release growth hormone (GH) in a pulsatile, physiologically natural pattern. It belongs to the GHRP (growth hormone-releasing peptide) class alongside GHRP-2 and GHRP-6, but stands out for its exceptional selectivity.
Unlike older GHRPs, Ipamorelin stimulates GH release without meaningfully spiking cortisol, prolactin, or ACTH — a profile that has made it a favorite in clinical peptide protocols.
Quick Facts
| Property | Detail |
|---|---|
| Type | Growth Hormone Secretagogue (GHS) / GHRP |
| Amino Acids | 5 |
| Molecular Weight | ~711 Da |
| Mechanism | Mimics ghrelin; binds GHS-R1a receptors on pituitary |
| Half-Life | ~2 hours |
| GH Release Pattern | Pulsatile (natural) |
| Regulatory Status | Category 2 → reclassification expected |
Mechanism: How It Differs from Other GHRPs
All GHRPs work by binding ghrelin receptors (GHS-R1a) on the pituitary to trigger GH release. Ipamorelin's advantage is its receptor selectivity:
| Peptide | GH Release | Cortisol Spike | Prolactin Spike | ACTH Spike |
|---|---|---|---|---|
| GHRP-6 | Strong | Yes | Yes | Yes |
| GHRP-2 | Strong | Moderate | Moderate | Moderate |
| Ipamorelin | Strong | Minimal | Minimal | Minimal |
This clean profile makes Ipamorelin more suitable for sustained clinical use and is why it is typically preferred over older GHRPs in compounding protocols.
The CJC-1295 + Ipamorelin stack is the most widely prescribed peptide combination in clinical practice. CJC-1295 (a GHRH analog) stimulates the pituitary to produce more GH, while Ipamorelin triggers its release — creating a synergistic "push-pull" effect.
Research Areas of Interest
- Body composition — studied for effects on lean mass and reduction of adipose tissue, particularly in GH-deficient populations
- Sleep quality — pulsatile GH release is tightly linked to slow-wave (deep) sleep; Ipamorelin's pattern may support sleep architecture
- GH deficiency — used in clinical settings as a GH-stimulating agent for patients with suboptimal GH production
- Recovery — research interest in tissue repair and injury recovery given GH's downstream effects on IGF-1
Dosing in Clinical Research
Ipamorelin is typically studied in the range of 100–300 mcg per injection, administered subcutaneously. It is most commonly dosed 1–2× daily, often before sleep to align with natural GH pulse timing.
When combined with CJC-1295, the combination is typically dosed together in a single injection (pre-mixed combo vials are standard through compounding pharmacies).
Side Effects
Ipamorelin has one of the cleaner side-effect profiles in the GHRP class:
- Mild water retention — common, especially early in use; usually transient
- Increased hunger — ghrelin-mediated; more pronounced at higher doses
- Tingling or numbness — reported by some users, likely related to GH-mediated fluid shifts
- Headache — occasional, typically mild
Significant cortisol or hormonal disruption is not expected at clinical doses due to Ipamorelin's receptor selectivity.
Regulatory Status
Ipamorelin is currently classified as Category 2 under FDA rulemaking, meaning it cannot be legally compounded or prescribed in the United States at this time.
The FDA has announced a reclassification process expected to be finalized in 2026. Ipamorelin is one of the 14 peptides expected to move to Category 1, which would restore legal compounding access through licensed 503A and 503B pharmacies.
How Valitide Will Offer Ipamorelin
Once the FDA reclassification is finalized, Valitide will offer Ipamorelin through licensed telehealth providers and vetted 503A/503B compounding pharmacies. All prescriptions will require:
- Evaluation by a licensed physician or nurse practitioner
- A valid patient-specific prescription
- Dispensing from a licensed compounding pharmacy meeting USP sterile compounding standards
Ipamorelin will most likely be offered as part of a CJC-1295 + Ipamorelin combination protocol, consistent with standard clinical practice.
Join the waitlist to be notified when prescription access becomes available.